Indication
Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig.
Loading your page…
Loading your page…
Migraine Disorders
Marketing Authorisation Holder: Novartis Europharm Limited
EMA Authorisation: 26/07/2018
INN: erenumab
AI Drug & Interaction Analysis
Free account required
Ask Osler about Aimovig: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.